Evidence map›Paper›PMID 24685638›Full record

ArticleEuropean journal of pharmacology2014

Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Michelle G Baladi, Amy H Newman, Shannon M Nielsen, Glen R Hanson, Annette E Fleckenstein

Open access · greenAbstract read
In one paragraph

Article in European journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. A Mechanistic Review on Toxicity Effects of Methamphetamine.International journal of medical sciences · 2025
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Heightened Dopaminergic Response to Amphetamine at the DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michelle G BaladiDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA.
Amy H NewmanMedicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Shannon M NielsenDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA.
Glen R HansonDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA; School of Dentistry, University of Utah, Salt Lake City, Utah, USA.
Annette E FleckensteinDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA. Electronic address: fleckenstein@hsc.utah.edu.
University of Utah · USNational Institute on Drug Abuse · US

Funding

Novel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9M
Vmat AND NEUROTOXICITYP01DA013367 · NIDA · UNIVERSITY OF UTAH · PI HANSON, GLEN R · 2001 to 2012
$10.1M
DRUG ABUSE &REGULATORY ENZYMES OF BIOGENIC AMINESR01DA000869 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 1985 to 2010
$2.9M
Psychostimulants and Monoamine TransportersR01DA011389 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 2003 to 2012
$2.5M
Role of Neurotensin Systems in Methamphetamine Self AdministrationR01DA031883 · NIDA · UNIVERSITY OF UTAH · PI HANSON, GLEN R · 2012 to 2016
$1.5M
K02 ApplicationK02DA019447 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 2005 to 2014
$1.3M
Pharmacology and Toxicology of Methamphetamine Abuse (K05 DA00378)K05DA000378 · NIDA · UNIVERSITY OF UTAH · PI HANSON, GLEN R · 1998 to 2011
$1.2M
METHAMPHETAMINE AND DOPAMINE TRANSPORTERSR29DA011389 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 1998 to 2002
$329k
NIDA NIH HHS DA00378NIDA NIH HHS DA00869NIDA NIH HHS DA019447NIDA NIH HHS DA11389NIDA NIH HHS DA13367NIDA NIH HHS K02 DA019447NIDA NIH HHS K05 DA000378NIDA NIH HHS P01 DA013367NIDA NIH HHS R01 DA000869NIDA NIH HHS R01 DA011389NIDA NIH HHS R01 DA031883NIDA NIH HHS R29 DA011389
6 · The paper itself

Abstract

Methamphetamine administration causes long-term deficits to dopaminergic systems that, in humans, are thought to be associated with motor slowing and memory impairment. Methamphetamine interacts with the dopamine transporter (DAT) and increases extracellular concentrations of dopamine that, in turn, binds to a number of dopamine receptor subtypes. Although the relative contribution of each receptor subtype to the effects of methamphetamine is not fully known, non-selective dopamine D2/D3 receptor antagonists can attenuate methamphetamine-induced changes to dopamine systems. The present study extended these findings by testing the role of the dopamine D3 receptor subtype in mediating the long-term dopaminergic, and for comparison serotonergic, deficits caused by methamphetamine. Results indicate that the dopamine D3 receptor selective antagonist, PG01037, attenuated methamphetamine-induced decreases in striatal DAT, but not hippocampal serotonin (5HT) transporter (SERT), function, as assessed 7 days after treatment. However, PG01037 also attenuated methamphetamine-induced hyperthermia. When methamphetamine-induced hyperthermia was maintained by treating rats in a warm ambient environment, PG01037 failed to attenuate the effects of methamphetamine on DAT uptake. Furthermore, PG01037 did not attenuate methamphetamine-induced decreases in dopamine and 5HT content. Taken together, the present study demonstrates that dopamine D3 receptors mediate, in part, the long-term deficits in DAT function caused by methamphetamine, and that this effect likely involves an attenuation of methamphetamine-induced hyperthermia.

Indexed as

AnimalsCentral Nervous System StimulantsDopamineDopamine AntagonistsDopaminergic NeuronsFeverHippocampusMaleMethamphetamineRatsRats, Sprague-DawleyReceptors, Dopamine D3SerotoninSynaptosomesCentral Nervous System StimulantsDopamineDopamine AntagonistsMethamphetamineReceptors, Dopamine D3SerotoninD(3) antagonistDopamine D(3) receptorsDopamine transporterMethamphetaminePG01037Serotonin transporter

Identifiers

PMID24685638
PMCPMC4060957
OpenAlexW2083069261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.